dovepress.com
Cure8 news brief
Why This Matters
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
It reports real-world effectiveness, safety, treatment persistence, and exploratory drug level (plasma concentration) correlations with endoscopic results, which may help clinicians and patients understand how the drug performs outside trials.
Who Should Pay Attention
Adults with moderate-to-severe Crohn’s disease, especially those who failed anti-TNF therapy; clinicians treating IBD; and researchers studying JAK inhibitors, drug levels, and biomarkers.
Study Snapshot
Story typeResearch paper
Evidence typeObservational study
Source depthFull source text
What To Know
This paper reports a retrospective real-world study from a Chinese tertiary center evaluating upadacitinib (a JAK1 inhibitor) in adults with moderate-to-severe Crohn’s disease who failed prior anti-TNF therapy.
The authors collected clinical scores (HBI), endoscopic scores (SES-CD), laboratory markers (CRP, fecal calprotectin, hemoglobin, albumin), treatment persistence, safety events, and measured plasma upadacitinib concentrations to explore associations with endoscopic outcomes.
The study population is anti-TNF refractory and includes patients with complex disease and prior biologic exposure; endoscopy timing and plasma sampling were performed in routine practice (endoscopy often ~6 months, blood 24 hours after a dose).
The report focuses on real-world effectiveness, persistence, safety, and exploratory drug level–outcome relationships in a Chinese cohort. No treatment recommendations are provided in the article text. The findings add real-world data to complement phase 3 trials of upadacitinib and include an Asian population often underrepresented in trials.
Readers should look to the full text for specific outcome measures, sample size, and safety event details.
Keep In Mind
This is a retrospective, single-center real-world cohort from China; such studies help supplement randomized trial data but have limitations (selection bias, variable follow-up, nonstandardized assessments). Plasma drug concentration analyses are exploratory and do not by themselves establish clinical guidelines or clear exposure-response thresholds.
Source Details
Review the original publication for the complete reporting, methods, and context.
Observational study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationdovepress.com
Indexed viaGoogle News
Source typeResearch paper
PublishedMay 4, 2026, 6:14 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
TNF inhibitors might help prevent serious complications in kids with Crohn's Disease
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
Do You Need to Treat Asymptomatic Crohn’s Disease?
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
Why anti-TNF drugs don't work for some kids with Crohn's disease - Medical Xpress
This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.